Wave regains full rights to WVE-006; plans FDA accelerated approval engagement mid-2026

Wave Life Sciences Ltd.

Regained full rights to WVE-006 (RNA editing for AATD) from GSK; no upfront payment mentioned.
Plans to engage FDA on accelerated approval pathway; regulatory feedback expected mid-2026.
400 mg multidose cohort data from RestorAATion-2 on track for Q1 2026; 600 mg data expected in 2026.
GSK collaboration continues; fourth program selected in Jan 2026; potential milestones up to $2.8B.
Cash runway expected into Q3 2028; milestone payments from GSK not included in runway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.